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NK105 is a micellar nanoparticle formulation designed to enhance the delivery of paclitaxel (PTX) to solid tumours. It has been
reported to exert antitumour activity in vivo and to have reduced neurotoxicity as compared to that of free PTX. The purpose of this
study was to investigate the radiosensitising effect of NK105 in comparison with that of PTX. Lewis lung carcinoma (LLC)-bearing
mice were administered a single intravenous (i.v.) injection of PTX or NK105; 24h after the drug administration, a proportion of the
mice received radiation to the tumour site or lung fields. Then, the antitumour activity and lung toxicity were evaluated. In one subset
of mice, the tumours were excised and specimens were prepared for analysis of the cell cycle distribution by flow cytometry.
Combined NK105 treatment with radiation yielded significant superior antitumour activity as compared to combined PTX treatment
with radiation (P¼0.0277). On the other hand, a histopathological study of lung sections revealed no significant difference in
histopathological changes between mice treated with PTX and radiation and those treated with NK105 and radiation. Flow-
cytometric analysis showed that NK105-treated LLC tumour cells showed more severe arrest at the G2/M phase as compared to
PTX-treated tumour cells. The superior radiosensitising activity of NK105 was thus considered to be attributable to the more severe
cell cycle arrest at the G2/M phase induced by NK105 as compared to that induced by free PTX. The present study results suggest
that further clinical trials are warranted to determine the efficacy and feasibility of combined NK105 therapy with radiation.
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Paclitaxel (PTX) has been demonstrated to be one of the most
effective anticancer agents available at present (Carney, 1996;
Khayat et al, 2000). Besides its antitumour activity, its ability to
induce radiosensitisation has been reported both in vitro (Tishler
et al, 1992; Choy et al, 1993; Lokeshwar et al, 1995; Rodriguez et al,
1995) and in vivo (Milas et al, 1994, 1995; Cividalli et al, 1998) this
effect has been attributed to its effect of stabilising microtubules
and inducing cell cycle arrest at the G2/M phase, the most
radiosensitive phase of the cell cycle (Terasima and Tolmach, 1963;
Sinclair and Morton, 1966). As several clinical studies have
demonstrated the efficacy of PTX-based chemotherapy combined
with radiotherapy, the combined modality is considered to be a
potentially important treatment option for lung and breast cancer
(Choy et al, 1998a,b, 2000; Dowell et al, 1999; Formenti et al, 2003;
Kao et al, 2005).
The adverse effects of radiation, namely, lung toxicities in
patients with breast or lung cancer treated by thoracic radiation,
are of great concern, and may be dose limiting or even have a
negative impact on the quality of life of the patients, even though
radiation is an efficient treatment option. Lung toxicities often
result in lung fibrosis, necessitating change of the treatment
method and causing much distress or even death of the patients
(Penney and Rubin, 1977; Early Breast Cancer Trialists’ Colla-
borative Group, 2000; Lind et al, 2002). Some clinical trials actually
reported an increased incidence of pneumonitis following
combined PTX therapy with radiation in patients with breast or
lung cancer (Taghian et al, 2001; Hanna et al, 2002; Chen and
Okunieff, 2004).
Although widely used, PTX itself has several adverse effects,
such as peripheral sensory neuropathy (Rowinsky et al, 1993;
Rowinsky and Donehower, 1995), and its poor solubility in water is
also associated with such effects as anaphylaxis and other severe
hypersensitivity reactions attributable to Cremophor EL and
ethanol, which are essential for solubilising PTX (Weiss et al,
1990; Rowinsky and Donehower, 1995). In order to overcome these
problems, we prepared a new formulation, NK105, which is a PTX-
incorporating polymeric micellar nanoparticle (85nm in size)
(Hamaguchi et al, 2005). NK105 is formed by facilitating the
self-association of amphiphilic block copolymers constructed
using polyethylene glycol (PEG) as the hydrophilic segment and
modified polyaspartate as the hydrophobic segment in an aqueous
medium. Owing to the PEG constituting the outer shell of the
micelles, NK105 is soluble in water. In addition, PEG also confers a
stealth property to the formulation, that allows the micellar drug
preparation to be less avidly taken up by the reticuloendothelial
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ssystem (RES) and to be retained in the circulation for a longer
period of time (Klibanov et al, 1990, 1991; Allen, 1994; Gabizon
et al, 1996). The prolonged circulation time and the ability of
NK105 to extravasate through the leaky tumour vasculature (i.e.,
the EPR (enhanced permeability and retention) effect) causes
accumulation of PTX in tumour tissues (Matsumura and Maeda,
1986; Maeda and Matsumura, 1989). We previously demonstrated
that NK105 is associated with reduced neurotoxicity and also
exerts more potent antitumour activity on human cancer
xenograft, as compared to free PTX. In addition, because of its
solubility in water, it is expected that the incidence of anaphylaxis
and hypersensitivity reactions attributable to Cremophor EL and
ethanol may also be reduced with NK105. A clinical trial of NK105
is now under way.
In this context, it is expected that the use of NK105 in place of
PTX in combination with radiation may also yield superior
results, because of the more potent antitumour activity of this
drug as compared to that of free PTX. In this study, we evaluated
the antitumour activity and severity of lung fibrosis induced by
PTX and NK105 administered in combination with thoracic
radiation, to examine whether combined NK105 chemotherapy
with radiation would be an acceptable or useful treatment
modality.
MATERIALS AND METHODS
Mice
Eight-week-old female C57BL/6J mice were purchased from
Charles River Japan Inc. (Kanagawa, Japan). All the animal
procedures were performed in compliance with the guidelines
for the care and use of experimental animals, drawn up by the
Committee for Animal Experimentation of the National Cancer
Center; these guidelines meet the ethical standards required by law
and also comply with the guidelines for the use of experimental
animals in Japan.
PTX and NK105
Paclitaxel was purchased from Merican Corp. (Tokyo, Japan).
NK105 is a PTX-incorporating ‘core-shell-type’ polymeric micellar
nanoparticle formulation that was prepared by a previously
reported procedure (Hamaguchi et al, 2005). Briefly, polymeric
micellar particles were formed by facilitating the self-association of
amphiphilic block copolymers in an aqueous medium. The
polymer of NK105 was constructed using PEG as the hydrophilic
segment and modified polyaspartate as the hydrophobic segment.
The carboxylic groups of the polyaspartate block were modified by
the esterification reaction with 4-phenyl-1-butanol, resulting in
conversion of half of the groups to 4-phenyl-1-butanolate.
Molecular weight of the polymers was determined to be
approximately 2000 (PEG block: 12000; moditied polyaspartate
block: 8000).
Via the self-association process, PTX was incorporated into the
inner core of the micelle system by physical entrapment through
hydrophobic interactions between the drug and specifically well-
designed block copolymers for PTX. NK105 was obtained as a
freeze-dried formulation and contained ca.23% (WW
 1) of PTX.
Finally, NK105, PTX-incorporating polymeric micellar nanoparti-
cle formulation with a single and narrow size distribution, was
obtained. The weight-average diameter of the nanoparticles was
approximately 85nm ranging from 20 to 430nm.
Irradiation
The mice were anesthetised by intraperitoneal (i.p.) injection of
nembutal (75mgkg
 1) and placed on the stage for irradiation. The
whole thorax or subcutaneous (s.c.) tumours of the thigh were
irradiated using a Faxitron cabinet X-ray system model CP-160 by
100kV X-rays from a linear accelerator, at a dose rate of
2Gymin
 1. Totally 12Gy was irradiated to each mouse. The
whole body except irradiated parts, lung field or tumour lesion,
were shielded with specially designed lead blocks.
Flow cytometry
At 24h after the injection of PTX or NK105 into the Lewis lung
carcinoma (LLC) tumour-bearing C57BL/6j mice, the tumours
were excised, minced in PBS, and fixed in 70% ethanol at 41C for
48h. After being fixed, the tumours were digested with 0.04%
pepsin (Sigma chemical co., St Louis, MO, USA) in 0.1 N HCl for
60min at 371C in a shaking bath for preparing single-nuclei
suspensions. The nuclei were then centrifuged, washed twice with
PBS, and stained with 40mgml
 1 of propidium iodide (Molecular
Probes, OR, USA) in the presence of 100mgml
 1 RNase in 1ml
PBS for 30min at 371C. The stained nuclei were analysed with a
B-D FACSCalibur (BD Biosciences, San Jose, CA, USA). The cell
cycle distribution was analysed using the Modfit program (Verity
Software House Inc., Topsham, ME, USA).
Evaluation of the antitumour activity
For this experiment, 3 10
6 LLC cells were inoculated s.c. into the
right thighs of mice. The tumour volume was calculated using the
formula, tumour volume (mm
3)¼a b
2/2 (a¼longest tumour
diameter, b¼shortest tumour diameter). When the tumour
volume reached approximately 100mm
3 on day 14 after the
tumour inoculation, the mice were randomly allocated to test
groups of about four or five mice each, and started the treatment
on the same day. There were six test groups, as follows: untreated
control, PTX treatment alone, NK105 treatment alone, radiation
alone, combined PTX treatment with radiation, and combined with
NK105 treatment with radiation.
In the groups receiving PTX or NK105, the mice were
administered a single intravenous (i.v). injection of PTX or
NK105 at the dose of 45mgkg
 1; 24h after the drugs were
administered, the tumour sites of the mice in the groups scheduled
to receive radiation were irradiated.
The antitumour activity of each treatment regimen was
evaluated by measuring the tumour volume. Tumour volume
and body weight was measured every 3 days.
Evaluation of lung toxicity
The severity of lung toxicity was evaluated histologically in the
following test groups; untreated control (n¼6), radiation treat-
ment alone (n¼6), combined PTX treatment with radiation
(n¼9), and combined NK105 treatment with radiation (n¼10).
Mice were administered a single i.v. injection of PTX or NK105 at
the dose of 45mgkg
 1; 24h after the drugs were administered, the
thorax of the mice in the groups scheduled to receive radiation was
irradiated. All the mice were killed 36 weeks after the drug
administration. At the time of the killing, the lungs were removed,
and the right lungs were fixed in 10% buffered formalin for 24h,
then embedded in paraffin. The lungs were inflated at 20cm water
pressure by intratracheal infusion of 10% buffered formalin before
fixation. Sections (5mm- thick) were stained with haematoxylin
and eosin (H&E) and observed under the light microscope. The
severity of the pulmonary fibrosis was assessed based on
Ashcroft’s scoring system (Ashcroft et al, 1988). Briefly, all the
fields of each lung section were scanned under a Leica microscope
at a magnification of  100, then each field was visually graded
from 0 (normal lung) to 8 (total fibrotic obliteration of the field).
The mean grades obtained for all of the fields was then calculated
as the visual fibrotic score.
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sImmunohistochemistry
The lung sections were deparaffinised and rehydrated, then
microwaved in 0.01 M sodium citrate buffer for 15min at 901Ct o
retrieve epitopes, and cooled at room temperature. An endogenous
peroxidase blocking solution of 3% hydrogen peroxide was applied
for 20min at room temperature. After blocking the nonspecific
binding sites with 2% normal goat serum, the sections were
incubated with rabbit anti-mouse collagen III immunoglobulin G
(IgG) (Chemicon International, Temecula, CA, USA) overnight at
41C. The sections were then washed with PBS, followed by the
addition of biotin-conjugated goat anti-rabbit IgG (Vector
Laboratories Inc., Burlingame, CA, USA) and incubation for
30min at room temperature. The sections were then washed and
incubated with horseradish-peroxidase-conjugated avidin–biotin
complex (Vector Laboratories Inc., Burlingame, CA, USA) at room
temperature for 30min, in accordance with the manufacturer’s
instructions (Vector Laboratories Inc.). The immunoreactions
were visualised using 3,30-diaminobenzidine as the substrate and
counterstaining with haematoxylin.
Statistical analysis
Date were expressed the mean7s.d. Differences between the test
groups were analysed by Student’s t-test. We used Stat View (SAS
Institute Inc.) statistical software. A value of Po0.05 was
considered statistically significant.
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Figure 1 Cell cycle analysis. Cell cycle analysis of LLC tumour cells 24h
after PTX (A) or NK105 administration (B). Untreated control cells are
shown in (C).
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Figure 2 Antitumour activity. Changes in the LLC tumour growth rates
in the mice. (A) Mice receiving TXL-alone (K), NK105-alone (J),
combined treatment with PTX and radiation (’), and combined
treatment with NK105 and radiation (&) were administered a single i.v.
injection of PTX or NK105 at the dose 45mgkg
 1 on day 14 after the
tumour inoculation (¼on day 0 after the initial treatment). After 24h the
drugs were administered, the mice in the radiation-alone (n) and the
combined-treatment groups were irradiated (arrow). Mice in the control
group ( ) were given no treatment. (B) Changes in the relative body
weight. Data were derived from the same mice as those used in the
present study.
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sRESULTS
Cell cycle analysis
At 24h after the administration of PTX or NK105 to the LLC-
tumour-bearing mice, severe cell cycle arrest at the G2/M phase
was observed in the tumour cells treated with the drugs as
compared with that in the control (no drug treatment) (Figure 1C).
There was a tendency towards the NK105-treated LLC tumour cells
(Figure 1B) showing more severe arrest at the G2/M phase than the
PTX-treated cells (Figure 1A).
Antitumour activity
Decreased tumour growth rates of the LLC tumours were observed
in the mice of the radiation alone, combined PTX with radiation,
and combined NK105 with radiation groups. No antitumour
activity was observed following treatment with either PTX or
NK105 alone, because LLC is primarily a PTX-resistant tumour.
Combined NK105 therapy with radiation yielded superior
antitumour activity as compared to both radiation alone
(P¼0.0047) and combined PTX therapy with radiation
(P¼0.0277) on the day 9 after the treatment initiation
(Figure 2A). No significant differences in body weight changes
were noted among the groups tested (Figure 2B).
Lung toxicities
Histopathological examination of the lung sections of all the mice
receiving radiation showed inflammatory cell infiltration, appear-
ance of intra-alveolar macrophages, and destruction of the alveolar
architecture. Major portions of the alveolar septa in the lung
sections prepared from the irradiated mice showed slight
thickening, although no massive structural destruction was
observed (Figure 3A). On the other hand, the lung sections
prepared from the control nonirradiated group showed no
significant histopathological changes (Figure 3B). Ashcroft’s
fibrosis scores in the groups of mice that received radiation
ranged from 0.975 to 1.426, with no significant differences among
the groups. The score in the control group was nearly zero. In the
groups receiving radiation, the severity of lung fibrosis differed
significantly among the mice within the same groups, as did the
Ashcroft’s scores, that is, the s.d. of the Ashcroft’s scores in the
mice receiving radiation was very high (Figure 3C).
Type III collagen deposition
Immunohistochemical analysis of lung sections prepared from the
mice receiving radiation revealed significant collagen deposition,
especially in the subpleural regions, while that of lung sections
prepared from the control group showed little collagen deposition.
There were no significant differences among the different groups
receiving radiation (Figure 3D).
DISCUSSION
It is well known that PTX enhances the radiosensitivity of tumour
cells by inducing cell cycle arrest at the G2/M phase, the most
radiosensitive phase of the cell cycle (Terasima and Tolmach, 1963;
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Figure 3 H&E staining of the lungs of C57BL/6J mice surviving 36 weeks after the thoracic radiation (A) and sham radiation (B). (C) Semiquantitative
analyses to estimate the severity of pulmonary fibrosis in the mice receiving sham radiation (&), thoracic radiation alone (’), combined PTX with radiation
( ), and combined NK105 with radiation ( ). H&E- stained lung tissue sections were assessed to estimate the severity of pulmonary fibrosis by visual
grading of fibrosis (Ashcroft’s score). Collagen III staining of the irradiated lungs of mice (D).
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sSinclair and Morton, 1966). Many reports have confirmed the
radiosensitising effect of PTX in different cell lines (Tishler et al,
1992; Choy et al, 1993; Lokeshwar et al, 1995; Rodriguez et al,
1995), in vivo experiments (Milas et al, 1994, 1995; Cividalli et al,
1998), and in several clinical trials of combined PTX with radiation
therapy according to different schedules (Dillman et al, 1990;
Arriagada et al, 1991; Morton et al, 1991; Furuse et al, 1999; Sause
et al, 2000; Chen et al, 2003). Chen et al (2003) examined the
optimal timing of PTX treatment and irradiation in relation to the
cell cycle, and recommended that radiation be given at least 5h
after PTX administration, because G2/M arrest of a lung cancer
cell line was shown to start at 4h after PTX treatment and to last
for 44h.
In our experimental model to evaluate the antitumour activity,
the tumours were irradiated 24h after a single i.v. injection of PTX
or NK105. No significant increase in the antitumour activity as
compared with that in the control (no treatment) was observed
following a single i.v. injection of either PTX or NK105 at the dose
of 45mgkg
 1; LLC tumours are known to be primarily resistant to
PTX. In fact, the IC50 of PTX against an LLC tumour cell line was
shown to be 84.1nM, which is about 10-fold higher than that of
NK105 against various cancer cell lines tested in our previous work
(Hamaguchi et al, 2005). Combined NK105 therapy with radiation
yielded superior antitumour activity as compared with radiation
alone or combined PTX therapy with radiation. This result
suggests that NK105 has a more potent radiosensitising effect
than PTX. In our study, there was a tendency towards NK105-
treated LLC tumour cells showing more severe arrest at the G2/M
phase as compared to PTX-treated cells at 24h after the injection
of the drugs, the timing of the radiation treatment, probably
because NK105 allows a higher concentration of PTX to be
maintained in the tumour than conventional PTX (Hamaguchi
et al, 2005). We suppose that this is the reason why NK105 exerted
more potent radiosensitising activity than PTX.
Next, we were concerned about the adverse effects of combined
NK105 therapy with radiation. New micellar drugs are designed
based on the idea that DDS can accumulate in the tumour
selectively, while showing reduced distribution in normal tissues.
We demonstrated that the incorporation of cisplatin into micelles
significantly reduced the nephrotoxicity and neurotoxicity of
cisplatin (Uchino et al, 2005). However, it was also shown that
micelle- incorporated cisplatin caused transient liver dysfunction
because it was trapped more avidly by the RES as compared to free
cisplatin, even though the PEG of the outer shell of the micelle
confers the so-called stealth effect.
In this study, our examination of the lung sections of mice
treated with NK105 and radiation revealed that the histopatholo-
gical changes such as inflammatory cell infiltration, appearance of
intra-alveolar macrophages, and destruction of the alveolar
architecture were induced by thoracic radiation and not by the
accumulation of NK105 in the lung. There were no significant
differences in the histopathological changes observed among the
mice treated by NK105 and radiation and mice treated by radiation
alone or PTX with radiation. The severity of lung fibrosis did not
differ significantly among the test groups either. Although some
clinical trials reported an increased incidence of pneumonitis and
esophagitis following combined PTX therapy with radiation
(Taghian et al, 2001; Hanna et al, 2002; Chen and Okunieff,
2004), others reported no influence on the incidence of such
adverse effects (Ellerbroek et al, 2003; Yu et al, 2003). Several
clinical trials and in vivo experiments have discussed the subject,
however, no definitive conclusion has been arrived at (Mason et al,
1995; Choy et al, 1998; Yu et al, 2004; Kao et al, 2005). In our study,
in regard to the incidence of esophagitis, there were no significant
differences in the histopathological changes observed in the
esophageal sections at one week after the treatment among the
test groups (data not shown).
In conclusion, we demonstrated that combined NK105 chemo-
therapy with radiation exerts significant antitumour activity.
Furthermore, the lung toxicity of this combined treatment
modality was also acceptable as compared with that observed
following radiation alone or combined PTX therapy with radiation.
However, further studies are necessary to determine the effective-
ness of NK105 in terms of its radiosensitising effect.
ACKNOWLEDGEMENTS
We thank Drs K Sugiyama and K Tsuchihara for their scientific
advice and Mrs C Kanai and Mrs N Mie for their technical
assistance. We are also grateful to Mrs K Shiina for her secretarial
assistance. This work was supported by a Grant-in-Aid from the
Ministry of Health, Labor and Welfare of Japan (Y Matsumura)
and a Grant-in-Aid for Scientific Research on Priority Areas from
the Ministry of Education, Culture, Sports, Science and Technology
(Y Matsumura).
REFERENCES
Allen TM (1994) Long-circulating (sterically stabilized) liposomes for
targeted drug delivery. Trends Pharmacol Sci 15: 215–220
Arriagada R, Le Chevalier T, Quoix E, Ruffie P, de Cremoux H, Douillard
JY, Tarayre M, Pignon JP, Laplanche A (1991) ASTRO (American Society
for Therapeutic Radiology and Oncology) plenary: Effect of chemo-
therapy on locally advanced non-small cell lung carcinoma: a
randomized study of 353 patients. GETCB (Groupe d’Etude et Traitement
des Cancers Bronchiques), FNCLCC (Federation Nationale des Centres
de Lutte contre le Cancer) and the CEBI trialists. Int J Radiat Oncol Biol
Phys 20: 1183–1190
Ashcroft T, Simpson JM, Timbrell V (1988) Simple method of estimating
severity of pulmonary fibrosis on a numerical scale. J Clin Pathol 41:
467–470
Carney DN (1996) Chemotherapy in the management of patients with
inoperable non-small cell lung cancer. Semin Oncol 23: 71–75
Chen Y, Okunieff P (2004) Radiation and third-generation chemotherapy.
Hematol Oncol Clin North Am 18: 55–80
Chen Y, Pandya K, Keng PC, Johnstone D, Li J, Lee YJ, Smudzin T, Okunieff
P (2003) Phase I/II clinical study of pulsed paclitaxel radiosensitization
for thoracic malignancy: a therapeutic approach on the basis of
preclinical research of human cancer cell lines. Clin Cancer Res 9:
969–975
Choy H, Akerley W, Safran H, Graziano S, Chung C, Williams T, Cole B,
Kennedy T (1998a) Multiinstitutional phase II trial of paclitaxel,
carboplatin, and concurrent radiation therapy for locally advanced
non-small-cell lung cancer. J Clin Oncol 16: 3316–3322
Choy H, Devore III RF, Hande KR, Porter LL, Rosenblatt P, Yunus F,
Schlabach L, Smith C, Shyr Y, Johnson DH (2000) A phase II study of
paclitaxel, carboplatin, and hyperfractionated radiation therapy for
locally advanced inoperable non-small-cell lung cancer (a Vanderbilt
Cancer Center Affiliate Network Study). Int J Radiat Oncol Biol Phys 47:
931–937
Choy H, Rodriguez FF, Koester S, Hilsenbeck S, Von Hoff DD (1993)
Investigation of taxol as a potential radiation sensitizer. Cancer 71:
3774–3778
Choy H, Safran H, Akerley W, Graziano SL, Bogart JA, Cole BF (1998b)
Phase II trial of weekly paclitaxel and concurrent radiation therapy
for locally advanced non-small cell lung cancer. Clin Cancer Res 4:
1931–1936
Cividalli A, Arcangeli G, Cruciani G, Livdi E, Cordelli E, Danesi DT (1998)
Enhancement of radiation response by paclitaxel in mice according to
different treatment schedules. Int J Radiat Oncol Biol Phys 40: 1163–1170
Dillman RO, Seagren SL, Propert KJ, Guerra J, Eaton WL, Perry MC, Carey
RW, Frei III EF, Green MR (1990) A randomized trial of induction
Enhancement of tumour radioresponse by NK105
T Negishi et al
605
British Journal of Cancer (2006) 95(5), 601–606 & 2006 Cancer Research UK
T
r
a
n
s
l
a
t
i
o
n
a
l
T
h
e
r
a
p
e
u
t
i
c
schemotherapy plus high-dose radiation vs radiation alone in stage III
non-small-cell lung cancer. N Engl J Med 323: 940–945
Dowell JE, Sinard R, Yardley DA, Aviles V, Machtay M, Weber RS,
Weinstein GS, Chalian AA, Carbone DP, Rosenthal DI (1999) Seven-week
continuous-infusion paclitaxel concurrent with radiation therapy for
locally advanced non-small cell lung and head and neck cancers. Semin
Radiat Oncol 9: 97–101
Early Breast Cancer Trialists’ Collaborative Group (2000) Favourable and
unfavourable effects on long-term survival of radiotherapy for early
breast cancer: an overview of the randomised trials. Early Breast Cancer
Trialists’ Collaborative Group. Lancet 355: 1757–1770
Ellerbroek N, Martino S, Mautner B, Tao ML, Rose C, Botnick L (2003)
Breast-conserving therapy with adjuvant paclitaxel and radiation
therapy: feasibility of concurrent treatment. Breast J 9: 74–78
Formenti SC, Volm M, Skinner KA, Spicer D, Cohen D, Perez E, Bettini AC,
Groshen S, Gee C, Florentine B, Press M, Danenberg P, Muggia F (2003)
Preoperative twice-weekly paclitaxel with concurrent radiation therapy
followed by surgery and postoperative doxorubicin-based chemotherapy
in locally advanced breast cancer: a phase I/II trial. J Clin Oncol 21:
864–870
Furuse K, Fukuoka M, Kawahara M, Nishikawa H, Takada Y, Kudoh S,
Katagami N, Ariyoshi Y (1999) Phase III study of concurrent vs
sequential thoracic radiotherapy in combination with mitomycin,
vindesine, and cisplatin in unresectable stage III non-small-cell lung
cancer. J Clin Oncol 17: 2692–2699
Gabizon A, Chemla M, Tzemach D, Horowitz AT, Goren D (1996) Liposome
longevity and stability in circulation: effects on the in vivo delivery to
tumors and therapeutic efficacy of encapsulated anthracyclines. J Drug
Target 3: 391–398
Hamaguchi T, Matsumura Y, Suzuki M, Shimizu K, Goda R, Nakamura I,
Nakatomi I, Yokoyama M, Kataoka K, Kakizoe T (2005) NK105, a
paclitaxel-incorporating micellar nanoparticle formulation, can extend in
vivo antitumour activity and reduce the neurotoxicity of paclitaxel. Br J
Cancer 92: 1240–1246
Hanna YM, Baglan KL, Stromberg JS, Vicini FA, A Decker D (2002) Acute
and subacute toxicity associated with concurrent adjuvant radiation
therapy and paclitaxel in primary breast cancer therapy. Breast J 8:
149–153
Kao J, Conzen SD, Jaskowiak NT, Song DH, Recant W, Singh R, Masters
GA, Fleming GF, Heimann R (2005) Concomitant radiation therapy
and paclitaxel for unresectable locally advanced breast cancer: results
from two consecutive phase I/II trials. Int J Radiat Oncol Biol Phys 61:
1045–1053
Khayat D, Antoine EC, Coeffic D (2000) Taxol in the management of
cancers of the breast and the ovary. Cancer Invest 18: 242–260
Klibanov AL, Maruyama K, Beckerleg AM, Torchilin VP, Huang L (1991)
Activity of amphipathic poly(ethylene glycol) 5000 to prolong the
circulation time of liposomes depends on the liposome size and is
unfavorable for immunoliposome binding to target. Biochim Biophys
Acta 1062: 142–148
Klibanov AL, Maruyama K, Torchilin VP, Huang L (1990) Amphipathic
polyethyleneglycols effectively prolong the circulation time of liposomes.
FEBS Lett 268: 235–237
Lind PA, Marks LB, Hardenbergh PH, Clough R, Fan M, Hollis D,
Hernando ML, Lucas D, Piepgrass A, Prosnitz LR (2002) Technical
factors associated with radiation pneumonitis after local +/  regional
radiation therapy for breast cancer. Int J Radiat Oncol Biol Phys 52:
137–143
Lokeshwar BL, Ferrell SM, Block NL (1995) Enhancement of radiation
response of prostatic carcinoma by taxol: therapeutic potential for late-
stage malignancy. Anticancer Res 15: 93–98
Maeda H, Matsumura Y (1989) Tumoritropic and lymphotropic principles
of macromolecular drugs. Crit Rev Ther Drug Carrier Syst 6: 193–210
Mason KA, Milas L, Peters LJ (1995) Effect of paclitaxel (taxol) alone and in
combination with radiation on the gastrointestinal mucosa. Int J Radiat
Oncol Biol Phys 32: 1381–1389
Matsumura Y, Maeda H (1986) A new concept for macromolecular
therapeutics in cancer chemotherapy: mechanism of tumoritropic
accumulation of proteins and the antitumor agent smancs. Cancer Res
46: 6387–6392
Milas L, Hunter NR, Mason KA, Kurdoglu B, Peters LJ (1994) Enhancement
of tumour radioresponse of a murine mammary carcinoma by paclitaxel.
Cancer Res 54: 3506–3510
Milas L, Hunter NR, Mason KA, Milross CG, Saito Y, Peters LJ (1995) Role
of reoxygenation in induction of enhancement of tumour radioresponse
by paclitaxel. Cancer Res 55: 3564–3568
Morton RF, Jett JR, McGinnis WL, Earle JD, Therneau TM, Krook JE, Elliott
TE, Mailliard JA, Nelimark RA, Maksymiuk AW (1991) Thoracic
radiation therapy alone compared with combined chemoradiotherapy
for locally unresectable non-small cell lung cancer. A randomized, phase
III trial. Ann Intern Med 115: 681–686
Penney DP, Rubin P (1977) Specific early fine structural changes in the lung
irradiation. Int J Radiat Oncol Biol Phys 2: 1123–1132
Rodriguez M, Sevin BU, Perras J, Nguyen HN, Pham C, Steren AJ, Koechli
OR, Averette HE (1995) Paclitaxel: a radiation sensitizer of human
cervical cancer cells. Gynecol Oncol 57: 165–169
Rowinsky EK, Chaudhry V, Forastiere AA, Sartorius SE, Ettinger DS,
Grochow LB, Lubejko BG, Cornblath DR, Donehower RC (1993) Phase I
and pharmacologic study of paclitaxel and cisplatin with granulocyte
colony-stimulating factor: neuromuscular toxicity is dose-limiting. J Clin
Oncol 11: 2010–2020
Rowinsky EK, Donehower RC (1995) Paclitaxel (taxol). N Engl J Med 332:
1004–1014
Sause W, Kolesar P, Taylor SI, Johnson D, Livingston R, Komaki R, Emami
B, Curran Jr W, Byhardt R, Dar AR, Turrisi III A (2000) Final results of
phase III trial in regionally advanced unresectable non-small cell lung
cancer: Radiation Therapy Oncology Group, Eastern Cooperative
Oncology Group, and Southwest Oncology Group. Chest 117:
358–364
Sinclair WK, Morton RA (1966) X-ray sensitivity during the cell generation
cycle of cultured Chinese hamster cells. Radiat Res 29: 450–474
Taghian AG, Assaad SI, Niemierko A, Kuter I, Younger J, Schoenthaler R,
Roche M, Powell SN (2001) Risk of pneumonitis in breast cancer patients
treated with radiation therapy and combination chemotherapy with
paclitaxel. J Natl Cancer Inst 93: 1806–1811
Terasima T, Tolmach LJ (1963) X-ray sensitivity and DNA synthesis in
synchronous populations of HeLa cells. Science 140: 490–492
Tishler RB, Geard CR, Hall EJ, Schiff PB (1992) Taxol sensitizes human
astrocytoma cells to radiation. Cancer Res 52: 3495–3497
Uchino H, Matsumura Y, Negishi T, Koizumi F, Hayashi T, Honda T,
Nishiyama N, Kataoka K, Naito S, Kakizoe T (2005) Cisplatin-
incorporating polymeric micelles (NC-6004) can reduce nephrotoxicity
and neurotoxicity of cisplatin in rats. Br J Cancer 93: 678–687
Weiss RB, Donehower RC, Wiernik PH, Ohnuma T, Gralla RJ, Trump DL,
Baker Jr JR, Van Echo DA, Von Hoff DD, Leyland-Jones B (1990)
Hypersensitivity reactions from taxol. J Clin Oncol 8: 1263–1268
Yu TK, Whitman GJ, Thames HD, Strom E, McNeese MD, Perkins GH,
Schechter N, Kau S, Buzdar AU, Hortobagyi GN, Thomas E, Buchholz TA
(2003) Clinically-relevant pneumonitis is not increased in breast cancer
patients treated with sequential paclitaxel and radiation. Int J Radiat
Oncol Biol Phys 57(2 Suppl): S127–S128
Yu TK, Whitman GJ, Thames HD, Buzdar AU, Strom EA, Perkins GH,
Schechter NR, McNeese MD, Kau SW, Thomas ES, Hortobagyi GN,
Buchholz TA (2004) Clinically relevant pneumonitis after sequential
paclitaxel-based chemotherapy and radiotherapy in breast cancer
patients. J Natl Cancer Inst 96: 1676–1681
Enhancement of tumour radioresponse by NK105
T Negishi et al
606
British Journal of Cancer (2006) 95(5), 601–606 & 2006 Cancer Research UK
T
r
a
n
s
l
a
t
i
o
n
a
l
T
h
e
r
a
p
e
u
t
i
c
s